1689 – Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized placebo-controlled trial

2013 ◽  
Vol 28 ◽  
pp. 1 ◽  
Author(s):  
U.W. Preuss ◽  
N. Bachinskaya ◽  
R. Kaschel ◽  
J.W. Wong ◽  
R. Hoerr ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Ginkgo Biloba ◽  
Controlled Trial ◽  
Neuropsychiatric Symptoms ◽  
Ginkgo Biloba Extract ◽  
Egb 761

scholarly journals Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®)

2021 ◽  
Vol 14 (4) ◽  
pp. 305
Author(s):  
Carlo Tomino ◽  
Sara Ilari ◽  
Vincenzo Solfrizzi ◽  
Valentina Malafoglia ◽  
Guglielmo Zilio ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Combination Therapy ◽  
Cognitive Decline ◽  
Ginkgo Biloba ◽  
Neuropsychiatric Symptoms ◽  
The Elderly ◽  
Egb 761 ◽  
Age Related

Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761® for the treatment of dementia syndromes and EGb 761® combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761® in mixed therapy.

Sign in / Sign up

Export Citation Format

Share Document